C4 Therapeutics (CCCC) Equity Average (2019 - 2026)

C4 Therapeutics' Equity Average history runs 8 years deep, the most recent figure standing at $245.4 million for Q1 2026.

• In Q1 2026, Equity Average rose 19.39% year-over-year to $245.4 million; the TTM figure through Mar 2026 stood at $245.4 million (up 19.39% YoY), while the FY2025 annual figure was $236.3 million, up 2.27% from the prior year.
• Equity Average was $245.4 million for Q1 2026 at C4 Therapeutics, up from $205.5 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $377.1 million in Q1 2022 to a low of $164.2 million in Q3 2025.
• Historically, Equity Average has averaged $254.8 million across 5 years, with a median of $245.4 million in 2026.
• The sharpest annual moves came in 2022 and 2025: Equity Average jumped 38.5% in 2022, then tumbled 32.93% in 2025.
• A 5-year view of Equity Average shows it stood at $303.7 million in 2022, then declined by 23.92% to $231.1 million in 2023, then slipped by 0.76% to $229.3 million in 2024, then decreased by 10.39% to $205.5 million in 2025, then rose by 19.43% to $245.4 million in 2026.
• The last three Equity Average figures came in at $245.4 million (Q1 2026), $205.5 million (Q4 2025), and $164.2 million (Q3 2025), per Business Quant data.